Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Clinical and Translational Radiation Oncology|May 9, 2019
Isodose 20 Gy found as a threshold dose for radiation recall dermatitisN Scher, M C Vozenin, H Bouchaab, et al.
Revue Medicale Suisse|June 20, 2014
[Postoperative radiation therapy in lung carcinom]H Bouchaab, S Peters, M Ozsahin, et al.
The British Journal of Radiology|March 5, 2015
Stereotactic body radiotherapy with helical TomoTherapy for medically inoperable early stage primary and second-primary non-small-cell lung neoplasm: 1-year outcome and toxicity analysisA Casutt, H Bouchaab, C Beigelman-Aubry, et al.
Revue Medicale Suisse|July 5, 2011
[Melanoma: a new therapeutic era]G Berthod, K Homicsko, H Bouchaab, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|August 14, 2022
Lung stereotactic radiation therapy: Intercomparison of irradiation devices in terms of outcome and predictive factorsE Le Reun, A Casutt, A Durham, et al.
European Journal of Cancer (Oxford, England : 1990)|February 27, 2017
A PET-based nomogram for oropharyngeal cancersJ Castelli, A Depeursinge, V Ndoh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2024
Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR studyP-F Petit, D Daoudlarian, S Latifyan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2024
Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapyD Daoudlarian, A Segot, S Latifyan, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2021
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapyE Ghisoni, A Wicky, H Bouchaab, et al.
Pageof 1